Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

A blocked coronary artery causing an acute heart attack must be opened immediately with a stent procedure. However, if other ...

Update: This story has been corrected to reflect the source of 12-month data for the PRO-Kinetic device. It comes from the previous ENERGY Registry study, and not from the BIOHELIX-1 study. Biotronik ...

More than a fifth of all coronary stents given to Medicare patients at hospitals nationwide from 2019 to 2021 are medically unnecessary, driving more than $2.4 billion in unnecessary program spending ...

The delivery of coronary artery stents is a procedure that affects over 1 million patients each year in the United States. With an aging population, the declining cost of stents, and reimbursement ...

Please provide your email address to receive an email when new articles are posted on . Tryton Medical Inc. announced the FDA premarket approval of a stent designed for the treatment of coronary ...

Please provide your email address to receive an email when new articles are posted on . A novel stent for treating long coronary lesions met its primary performance goal at 1 year. The 48-mm stent was ...

WASHINGTON--(BUSINESS WIRE)--In the first six-year follow-up of a pivotal study of any drug-eluting stent, the clinical benefits of the CYPHER ® Sirolimus-eluting Coronary Stent compared to a ...

DUBLIN--(BUSINESS WIRE)--The "Global Coronary Stents Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Global Coronary Stents Market was valued at ...

PARIS, France—It’s not a stent in a traditional sense, nor a scaffold that completely disappears over time, but a new device—one that “unchains” itself over time—has cleared an early hurdle by proving ...

According to SNS Insider, the global Coronary Stent Market was valued at USD 7.26 billion in 2023 and is projected to reach USD 10.83 billion by 2032, growing at a CAGR of 4.55% during the forecast ...

A Johnson & Johnson (NYSE:JNJ) subsidiary allegedly issued a sham recall of its drug-eluting CoStar coronary stent and spiked a distribution deal with Biotronik AG that cost the German medical device ...